Arrow-right Camera

The Spokesman-Review Newspaper The Spokesman-Review

Thursday, October 22, 2020  Spokane, Washington  Est. May 19, 1883
Clear Night 34° Clear

Tag search results

Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.


FDA approves new, cheaper rival to EpiPen allergy shot

U.S. regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed. As the mom of a kid with severe peanut/nut allergies this is welcome news. Do you or anyone in your family need to carry ah Epi-Pen?

Consumer Confidential: Insulin price hikes aren’t sweet

A key feature of Republican plans to replace Obamacare is allowing market forces to boost innovation and competition among health care providers. “Unleashing the power of choice and competition is the best way to lower health care costs and improve quality,” declares House Speaker Paul Ryan in his conservative manifesto “A Better Way.”

EpiPen manufacturer will be a no-show at Senate hearing

Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.

Martin Shkreli debuts secret Wu-Tang album after Trump win

President-elect Donald Trump’s victory Tuesday has prompted embattled pharmaceutical executive Martin Shkreli to publicly debut some songs off the one-of-a-kind Wu-Tang Clan album he bought for $2 million last year.

Mylan CEO defends EpiPen cost to angry lawmakers

Outraged Republican and Democratic lawmakers on Wednesday grilled the head of pharmaceutical company Mylan about the significant cost increase of its lifesaving EpiPens and the profits for a company with sales in excess of $11 billion.

Gary Crooks: U.S. health care not a bargain

The reality is that patients in other countries are charged less for health care services and drugs across the board, because their governments make it so.

Mylan launching cheaper, generic version of EpiPen

Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients.